Loading...
Docoh

Dr. Reddy`s Laboratories (RDY)

Filed: 9 Dec 21, 7:21am

Exhibit 99.2

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

 

Tel      : +91 40 4900 2900

Fax     : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

 

December 9, 2021

 

Corporate Relationship DepartmentNational Stock Exchange of India Ltd.
BSE Limited“Exchange Plaza”
Dalal Street, FortBandra-Kurla Complex, Bandra (East),
Mumbai – 400 001Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /Fax Nos.: 022-26598120/ 26598237/
                 22722037 / 22722039                 26598238
  
Scrip Code: 500124Scrip Code: DRREDDY-EQ

 

Dear Sirs,

 

Sub: Press Release

 

Please find enclosed a Press Release on “Dr. Reddy's Laboratories announces the launch of Valsartan Tablets, USP in the U.S. Market”

 

This is for your information.

 

With regards,

 

/s/ Vivek Mittal 
Vivek Mittal 
Global General Counsel and Compliance Officer 

 

Encl: As above

 

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

         NSE IFSC Ltd.

 

 

 

 

 

DR. REDDY'S LABORATORIES LTD.CONTACT
Investor relationSMedia relationS
8-2-337, Road No. 3, Banjara Hills,AMIT AGARWALUSHA IYER
Hyderabad - 500034. Telangana, India.amita@drreddys.comushaiyer@drreddys.com

 

Dr. Reddy's Laboratories announces the launch of
Valsartan Tablets, USP in the U.S. Market

 

Hyderabad, India, December 09, 2021For Immediate Release

 

Hyderabad, India and Princeton, NJ, USA. December 09, 2021 - Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).

 

The Diovan® brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.

 

Dr. Reddy’s Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.

 

Please click here for full prescribing information including boxed warning: https://www.drreddys.com/pil/150084612-Valsartan-Tablets_Outsert-v_10.pdf

 

 

WARNING: FETAL TOXICITY

· When pregnancy is detected, discontinue Valsartan as soon as possible. (5.1)

· Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)

 

 

Diovan is a trademark owned or licensed by Novartis Corporation 
 
*IQVIA Retail and Non-Retail MAT October 2021

 

RDY-1021-377

 

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its businesses, Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

 

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2021. The company assumes no obligation to update any information contained herein.